[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Herbarium Laboratorio Botanico Ltda\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100573834","phase-1-evaluation-of-clinical-perceived-and-instrumental-efficacy-of-a-scar-gel-in-preventing-hypertrophic-scars-100573834",false,"NCT06751433","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel Versus Benchmark in Preventing Hypertrophic Scars and Improving Scar Appearance","Inclusion Criteria:\n\n1. Participants of both sexes aged between 18 and 70 years;\n2. Participants with recent scars (\\\u003C30 days);\n3. Participants with phototypes III to VI according to the Fitzpatrick scale;\n4. Agree to follow the trial procedures and attend the center on the days and times determined for evaluations;\n5. Understand, agree to and sign the free and informed consent form.\n6. Types of scars: cesarean section, breast implant or blunt cut injury.\n\nExclusion Criteria:\n\n1. Pregnancy or risk of pregnancy;\n2. History of atopic or allergic reactions to cosmetic products;\n3. Participants who are using topical antibiotics or other skin products on the same area being evaluated;\n4. Immunosuppression due to drugs or active diseases;\n5. Decompensated endocrine diseases;\n6. Relevant clinical history or current evidence of alcohol or other drug abuse;\n7. Known history or suspected intolerance to products in the same category;\n8. Intense sun exposure up to 15 days before the evaluation;\n9. Patients who are using topical antibiotics or other skin products on the same area being evaluated.","ALL","18 Years","70 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Evaluation of the safety and topical efficacy of a scar gel after 90 days of continuous use, comparing it to a benchmark for preventing hypertrophic scars and improving appearance, hydration and pigmentation.",[28,29,30,31,32,33],"Acceptability Study","Real-use Conditions","Safety and Efficacy","Topical Administration","Hypertrophic Scars","Keloid Scars","RECRUITING","2025-09-09",{"date":37,"type":38},"2025-09-11","ACTUAL",{"date":40,"type":38},"2025-04-03",{"date":42,"type":21},"2025-12",{"name":44,"class":45},"Herbarium Laboratorio Botanico Ltda","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100536067","phase-4-efficacy-and-safety-study-of-products-based-on-tribulus-terrestris-l-in-men-with-oligospermia-100536067","NCT06260007","Efficacy and Safety Study of Products Based on Tribulus Terrestris, L. in Men With Oligospermia","Inclusion Criteria:\n\n1. \\- Male;\n2. \\- Ages 25 and 60;\n3. \\- Diagnosis of oligospermia;\n4. \\- With sexual partner;\n5. \\- Indication of drug treatment with steroid hormones, precursors or analogues.\n\nExclusion Criteria:\n\n1. \\- Severe oligospermia\n2. \\- Anatomical change\n3. \\- Previous treatment for oligospermia or concomitant treatment with steroid, anabolic, hormonal precursors such as testosterone or analogues;\n4. \\- BMI 35;\n5. \\- Participant who presents liver enzyme and creatinine values above the upper limit of normality;\n6. \\- History of testicular cancer, or prostate cancer or any other condition that carries risks in this case increased testosterone;\n7. \\- Hypersensitivity to any ingredient present in the formulation;\n8. \\- Any criteria or clinical history that, in the investigator's opinion, could compromise the well-being and participant safety;\n9. \\- Proven infertility of the partner;\n10. \\- History of genetic disorder;\n11. \\- History of psychiatric disorder, serious or decompensated illness or any situation that, Investigator's discretion, puts the participant's safety at risk;\n12. \\- Active cancer at the discretion of the Investigator;\n13. \\- Participants with pregnant and breastfeeding partners;\n14. \\- Cycling and horse riding more than 3 hours per week;\n15. \\- Alcoholism characterized by the inability to control alcohol consumption according to WHO \"drinker excessive, whose dependence on alcohol is accompanied by mental, health and physics, relationships with others and social and economic behavior\". Source: https:\u002F\u002Fwww.cancer.gov\u002Fpublications\u002Fdictionaries\u002Fcancerterms\u002Fdef\u002Falcoholism;\n16. \\- Smoking greater than half a pack per day or equivalent.","MALE","25 Years","60 Years",{"count":56,"type":21},204,[58],"PHASE4","Efficacy and Safety of Products Based on Tribulus terrestris, L. in Men with Oligospermia. It is expected that the benefits of investigational products outweigh the risks that will be mitigated or carefully managed by the study team.",[61],"Oligospermia",{"date":63,"type":38},"2025-04-06",{"date":65,"type":38},"2024-07-12",{"date":67,"type":21},"2026-08-17",{"name":44,"class":45},1,""]